Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Michael Mancino

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPSY Psychiatry, College of Medicine
DivisionPSY PRI Faculty
Address4TH FL Psychiatric Research Institute
4224 Shuffield Dr.
Mail Slot # 843
Little Rock AR 72205
Phone501-526-8440
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Michael J. Mancino is a Professor in the UAMS Department of Psychiatry and the program director of the Center for Addiction Services and Treatment in the Psychiatric Research Institute.


    Collapse Research 
    Collapse research activities and funding
    4600053332     (MANCINO, MICHAEL)Oct 1, 2023 - Sep 30, 2024
    Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services
    ADAP Substance Abuse Treatment Clinic FY24
    Role: Principal Investigator
    4600051890     (MANCINO, MICHAEL)Jan 1, 2023 - Sep 29, 2024
    Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services
    SOR III Emergency Department Naloxone Project
    Role: Principal Investigator
    UG1DA020024     (MANCINO, MICHAEL)Mar 1, 2022 - Feb 29, 2024
    NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center
    CURB-2: Randomized, placebo-controlled trial of injectable naltrexone and monthly injectable buprenorphine for methamphetamine use
    Role: Principal Investigator
    3UG1DA013035     (MANCINO, MICHAEL)Jul 1, 2021 - Feb 28, 2026
    NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University
    CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
    Role: Principal Investigator
    3UG1DA013035-21S3     (MANCINO, MICHAEL)Jul 1, 2021 - Feb 28, 2026
    NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University
    CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
    Role: Principal Investigator
    UG1DA013035     (MANCINO, MICHAEL)Jul 1, 2021 - Feb 28, 2026
    NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University
    CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
    Role: Principal Investigator
    4600047964     (MANCINO, MICHAEL)Nov 20, 2020 - Sep 29, 2022
    Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services
    State Opioid Response Grant for MATRIARC and ECHO
    Role: Principal Investigator
    4600047965     (MANCINO, MICHAEL)Nov 20, 2020 - Sep 29, 2022
    Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Human Services
    Medication-Assisted Treatment Services using Opioid Use Disorder
    Role: Principal Investigator
    R21DA045246     (WRIGHT, PATRICIA B)Sep 30, 2018 - Aug 31, 2021
    NIH
    Improving Treatment Strategies for Prescription Opioid Use Disorder- Resubmission
    Role: Co-Investigator
    4600036835     (MANCINO, MICHAEL)Jul 1, 2016 - Sep 30, 2023
    Substance Abuse & Mental Health Services Administration - Pass Through: Arkansas Department of Health & Human Services
    ADAP Substance Abuse Treatment Clinic - Continuation - Continuation - Continuation - Continuation - Continuation
    Role: Principal Investigator
    R01DA039088     (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021
    NIH/Nat. Inst. on Drug Abuse
    Improving Treatment Outcomes for Prescription Opioid Dependence
    Role: Co-Principal Investigator
    R01DA039088     (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021
    NIH
    Improving Treatment Outcomes for Prescription Opioid Dependence
    Role: Co-Principal Investigator
    R21DA034824     (MANCINO, MICHAEL J)Aug 1, 2013 - Jul 31, 2016
    NIH
    Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
    Role: Principal Investigator
    R21DA034824     (MANCINO, MICHAEL J)Aug 1, 2013 - Jul 31, 2016
    NIH
    Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
    Role: Principal Investigator
    R21DA035325     (OLIVETO, ALISON)Apr 15, 2013 - Mar 31, 2016
    NIH/Nat. Inst. on Drug Abuse
    Improving Buprenorphine Detoxification Outcomes with Isradipine
    Role: Co-Investigator
    R21DA031837     (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015
    NIH/Nat. Inst. on Drug Abuse
    Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans
    Role: Co-Investigator
    R21DA029842     (OLIVETO, ALISON)Aug 1, 2011 - Jun 30, 2015
    NIH/Nat. Inst. on Drug Abuse
    Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
    Role: Co-Investigator
    P50DA018197     (OLIVETO, ALISON)Sep 1, 2009 - May 31, 2014
    NIH/Nat. Inst. on Drug Abuse - Pass Through: Baylor College of Medicine
    Efficacy of Carvedilol in Recently-Abstinent Psychostimulant Dependent Patients
    Role: Co-Investigator
    R01DA026916     (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013
    NIH/Nat. Inst. on Drug Abuse
    Monoamine Antagonist Therapies for Methamphetamine Abuse
    Role: Co-Investigator
    R01DA019999     (KILTS, CLINT)May 1, 2007 - Feb 28, 2012
    NIH/Nat. Inst. on Drug Abuse
    AN FMRI STUDY OF THE IMPACT OF STRESS ON DRUG ADDICTION
    Role: Co-Investigator
    P20RR020146     (GARCIA-RILL, EDGAR E.)Sep 16, 2004 - Apr 30, 2014
    NIH
    Center for Translational Neuroscience
    Role: Co-Investigator
    33     (MANCINO, MICHAEL)Jul 1, 2003 - Jun 30, 2014
    Arkansas Department of Health & Human Services
    University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic
    Role: Principal Investigator
    33-04     (MANCINO, MICHAEL)Jul 1, 2003 - Jun 30, 2014
    Arkansas Department of Health & Human Services
    University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic
    Role: Principal Investigator
    SAS Dept of HS #33-04     (MANCINO, MICHAEL)Jul 1, 2003 - Jun 30, 2014
    Arkansas Department of Health & Human Services
    University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic
    Role: Principal Investigator
    SASDeptofHS#33     (MANCINO, MICHAEL)Jul 1, 2003 - Jun 30, 2014
    Arkansas Department of Health & Human Services
    University of Arkansas for Medical Sciences - Substance Abuse Treatment Clinic
    Role: Principal Investigator
    R01DA013441     (OLIVETO, ALISON)Jul 1, 2000 - Dec 31, 2012
    NIH/Nat. Inst. on Drug Abuse
    Disulfiram for Cocaine Abuse in Methadone-Maintained Patients
    Role: Co-Investigator
    R01DA010017     (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012
    NIH/Nat. Inst. on Drug Abuse
    Opioid Antagonist Discrimination: A Model of Withdrawal
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Tsai PF, Oliveto AH, Landes RD, Mancino MJ. Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice. J Opioid Manag. 2023 Jul-Aug; 19(4):329-341. PMID: 37644791.
      View in: PubMed
    2. Thompson RG, Bollinger M, Mancino MJ, Hasin D, Han X, Bush KA, Kilts CD, James GA. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial. Trials. 2023 Apr 04; 24(1):255. PMID: 37016394.
      View in: PubMed
    3. Thompson RG, Bollinger M, Mancino M, Hasin D, Han X, Bush KA, Kilts CD, James GA. Smartphone intervention to optimize medication assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial. Res Sq. 2023 Feb 15. PMID: 36824884.
      View in: PubMed
    4. Gokarakonda SB, Boydstun JM, Yilanli M, Han X, Kumar N, Oliveto AH, Mancino MJ. Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2022 05; 31(3):219-225. PMID: 35243715.
      View in: PubMed
    5. Thompson RG, Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. J Psychopharmacol. 2021 11; 35(11):1420-1430. PMID: 34697965.
      View in: PubMed
    6. Phillips SJ, Oliveto A, Mancino MJ, Hendrickson HP. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum. Rapid Commun Mass Spectrom. 2021 Jul 31; 35(14):e9104. PMID: 33860565.
      View in: PubMed
    7. Coker JL, Ray-Griffith SL, McLeod C, Han X, Mancino M, Kearns GL, Stowe ZN. Clearance of buprenorphine during pregnancy and neonatal outcomes. Arch Womens Ment Health. 2021 12; 24(6):933-939. PMID: 33864131.
      View in: PubMed
    8. Kumar N, Mancino MJ, Thostenson JD, McGaugh J, Oliveto AH. Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial. Subst Abuse. 2020; 14:1178221820970926. PMID: 33281447.
      View in: PubMed
    9. Wilson MP, Cucciare MA, Porter A, Chalmers CE, Mullinax S, Mancino M, Oliveto AH. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids. Am J Emerg Med. 2020 03; 38(3):503-507. PMID: 31221474.
      View in: PubMed
    10. Nahata R, Mancino MJ, Thostenson J, Oliveto AH. Survey of Treatment Preferences for Opioid Use Disorder. Jacobs J Addict Ther. 2018; 5(3). PMID: 31131330.
      View in: PubMed
    11. Bashiri M, Mancino MJ, Stanick VA, Thostenson J, Kosten TR, Oliveto AH. Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict. 2017 Dec; 26(8):807-814. PMID: 29115703.
      View in: PubMed
    12. Kumar N, Stowe ZN, Han X, Mancino MJ. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2016 10; 25(7):542-8. PMID: 27629823.
      View in: PubMed
    13. Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, Bickel WK. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014 Dec; 82(6):964-72. PMID: 25090043.
      View in: PubMed
    14. Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014 Apr; 34(2):234-9. PMID: 24525654.
      View in: PubMed
    15. Kaley S, Mancino MJ, Messias E. Sadness, suicide, and drug misuse in Arkansas: results from the Youth Risk Behavior Survey 2011. J Ark Med Soc. 2014 Feb; 110(9):185-6. PMID: 24719998.
      View in: PubMed
    16. Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302. PMID: 23855333.
      View in: PubMed
    17. Atkinson TS, Sanders N, Mancino M, Oliveto A. Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. J Addict Med. 2013 Jul-Aug; 7(4):243-8. PMID: 23648640.
      View in: PubMed
    18. Oliveto A, Mancino M, Sanders N, Cargile C, Benjamin Guise J, Bickel W, Brooks Gentry W. Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. Eur J Pharmacol. 2013 Sep 05; 715(1-3):424-35. PMID: 23524089.
      View in: PubMed
    19. Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41. PMID: 21707811.
      View in: PubMed
    20. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011 Mar; 37(2):131-6. PMID: 21219261.
      View in: PubMed
    21. Bickel WK, Jones BA, Landes RD, Christensen DR, Jackson L, Mancino M. Hypothetical intertemporal choice and real economic behavior: delay discounting predicts voucher redemptions during contingency-management procedures. Exp Clin Psychopharmacol. 2010 Dec; 18(6):546-52. PMID: 21186929.
      View in: PubMed
    22. Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011 Jan 15; 113(2-3):184-91. PMID: 20828943.
      View in: PubMed
    23. Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse. 2010 May; 36(3):155-60. PMID: 20465373.
      View in: PubMed
    24. Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr; 19(2):169-77. PMID: 20163389.
      View in: PubMed
    25. Mancino MJ, McGaugh, J, Feldman, Z, Poling, J, Oliveto, A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in opioid-dependent cocaine abusers maintained on LAAM: A retrospective analysis. American Journal on Addictions. 2010; 19(2):169-177.
    26. McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, Oliveto A. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol. 2009 Oct; 29(5):488-91. PMID: 19745650.
      View in: PubMed
    27. Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis. Pharmacol Biochem Behav. 2008 Oct; 90(4):787-96. PMID: 18585405.
      View in: PubMed
    28. Mancino MJ, Pyne JM, Tripathi S, Constans J, Roca V, Freeman T. Quality-adjusted health status in veterans with posttraumatic stress disorder. J Nerv Ment Dis. 2006 Nov; 194(11):877-9. PMID: 17102715.
      View in: PubMed
    29. Smith GR, Burnam MA, Mosley CL, Hollenberg JA, Mancino M, Grimes W. Reliability and validity of the substance abuse outcomes module. Psychiatr Serv. 2006; 57(10):1452 - 1460.
    30. Mancino M, Cunningham MR, Davidson P, Fulton RL. Identification of the motor vehicle accident victim who abuses alcohol: an opportunity to reduce trauma. J Stud Alcohol. 1996; 57(6):652 - 658.
    31. Fulton RL, Everman D, Mancino M, Raque G. Ritual head computed tomography may unnecessarily delay lifesaving trauma care. Surg Gynecol Obstet. 1993; 176(4):327 - 332.
    32. Fulton RL, Flynn WJ, Mancino M, Bowles D, Cryer HM. Brain injury causes loss of cardiovascular response to hemorrhagic shock. J Invest Surg. 1993; 6(2):117 - 131.
    33. Kulkarni PS, Mancino M. Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res. 1993; 56(3):275 - 279.
    34. Mancino, MJ, Ohia EO, Kulkarni P. A Comparative Study between Cod Liver Oil and Liquid Lard Intake on Intraocular Pressure in Rabbits. Prostaglandins Leukot Essent Fatty Acids. 1992; 45(3):239-243.
    35. Ohia EO, Mancino M, Kulkarni PS. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits. J Ocul Pharmacol. 1992; 8(4):295 - 307.
    Mancino's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (129) concept(s)
    _
    Co-Authors Expand Description
    See all (17) people
    _
    Similar People Expand Description
    See all (33) people
    _
    Same Department Expand Description
    Search Department